| Similar Articles |
|---|
 |
Pharmaceutical Executive
April 1, 2007
Bill Trombetta |
Stealth Pharmas Big Pharma is different from the thousands of biotechs, specialty pharmas, generics makers, and other companies that make up Stealth Pharma. Yes, they have more money. But in what other ways are they different? And can we learn anything from the way Stealth Pharma competes?   |
Pharmaceutical Executive
September 1, 2010 |
Pharm Exec's Ninth Annual Industry Audit Professor Bill Trombetta takes a snapshot of the "Glamour 24" companies shaping the pharma industry this year and beyond. |
Pharmaceutical Executive
September 1, 2011 |
Pharm Exec's 10th Annual Industry Audit A survey of the landscape of pharma financials over the past year, and a look at which companies rode the wave to the top of the industry in delivering value to shareholders. |
Pharmaceutical Executive
September 1, 2012
Bill Trombetta |
Pharm Exec's 11th Annual Industry Audit: Busting the Tape With pharmaceuticals are eyed as a commodity purchase, those traditional high margins are getting harder to find. Shareholder value and profits now depends on finding pockets of "good" growth, in segments with long-term potential in serving an unmet medical need, with fewer players. |
Pharmaceutical Executive
September 1, 2005
Bill Trombetta |
2005 Industry Audit Who's really on top in the pharmaceutical industry? |
Pharmaceutical Executive
September 1, 2006
Bill Trombetta |
Industry Audit This fifth annual report dives deep into the numbers and comes up with the pharmaceutical industry's true top performers. |
Pharmaceutical Executive
September 1, 2014
Bill Trombetta |
13th Annual Industry Audit After a dip into negative territory in 2012, 2013 delivered a resurgence in sales revenues, but the turnaround only spotlights a larger trend: the growing divide between the big Pharmas and the more nimble players. |
Pharmaceutical Executive
September 1, 2014
William Looney |
13 Years Right Pharm Exec's latest Industry Audit sticks to the series' longtime standard of emphasizing transparent indicators of shareholder value. |
The Motley Fool
May 29, 2011
Andrew Tonner |
Does Watson Pharmaceuticals Deserve a Spot in Your Portfolio? Although Watson Pharmaceuticals doesn't look like a stock for your portfolio right now, the search doesn't end here. |
The Motley Fool
May 23, 2011
Andrew Tonner |
Does Amgen Deserve a Spot in Your Portfolio? Depending on your assessment of future growth, Amgen could certainly make a nice addition to your portfolio. |
Chemistry World
March 25, 2015
Dennis Lendrem |
Be careful what you wish for There is a big debate right now in the pharmaceutical industry, and specifically about measuring R&D productivity. It all comes down to a choice of metrics. |
The Motley Fool
November 29, 2010
Seth Jayson |
Here's How Teva Pharmaceutical May Be Failing You Here's the margin picture for Teva Pharmaceutical over the past few years. |
IndustryWeek
May 1, 2008
John Teresko |
Seven Emerging Trends in R&D Metrics More companies tracking 'true performance metrics'. |
The Motley Fool
August 24, 2010
David Meier |
Could Amgen Be a Multibagger? Strong returns on equity can generate powerful shareholder returns. |
The Motley Fool
October 26, 2010
Seth Jayson |
From Gross to Net at Gilead Sciences Here's the margin picture for Gilead Sciences over the past few years. |
The Motley Fool
October 5, 2011
Dan Caplinger |
Has Teva Pharmaceutical Become the Perfect Stock? Teva still looks poised to stay near perfection for the indefinite future. |
Pharmaceutical Executive
January 1, 2014
Stan Bernard |
The 7 Habits of Highly Effective Competitions Lessons to win in a shifting market dynamic |
The Motley Fool
June 9, 2005
Richard Gibbons |
Buying on Margins Profit margins are one useful tool for finding great stock values. |
Chemistry World
May 1, 2015
Rebecca Trager |
Generics firms in three-way takeover battle US-based Mylan is gunning for Irish rival Perrigo, but the deal is overshadowed by a bid for Mylan itself from Israel's powerhouse Teva. |
The Motley Fool
December 20, 2010
Brian Orelli |
A Good Fit. On the Surface. Digging a little deeper into Gilead's acquisition of Arresto. |
The Motley Fool
December 14, 2010
Seth Jayson |
Why the Street Should Love Teva Pharmaceutical's Earnings Over the past 12 months, Teva Pharmaceutical generated $3,303.0 million in free cash flow on net income of $2,939.0 million. |
Pharmaceutical Executive
September 1, 2010 |
Is There a Balm for Gilead? A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days? |
The Motley Fool
October 5, 2011
John Maxfield |
1 Killer Statistic of Amazing Retail Stocks A chain's productivity per square foot is one of the strongest indicators of past success. |
The Motley Fool
July 29, 2010
Brian Orelli |
This Best Biotech Is Cheaper Than You Think The cancer-drug specialist justifies its valuation quite effectively with a stellar second-quarter performance. |
Pharmaceutical Executive
September 1, 2012
William Looney |
The Margin Call Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns. |
CIO
October 1, 2003
Jack Keen |
Wanted: Metric Skeptics Accepting vague or irrelevant numbers for project value can lead to bad IT spending decisions. |
The Motley Fool
September 17, 2010
Ed Salwin |
Why the Stock Market Can Go Up Forever It's a thing called productivity. |
The Motley Fool
November 3, 2010
Brian Orelli |
Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits. |
Pharmaceutical Executive
January 21, 2014
Tim Powell |
Innovation: The Moneyball Test Successful innovation now has to align with key metrics of value; can an old baseball metaphor help guide the way? |
The Motley Fool
April 29, 2005
Charly Travers |
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc. |
The Motley Fool
May 24, 2011
Andrew Tonner |
Does Eli Lilly Deserve a Spot in Your Portfolio? A quick check of the numbers should help get us started. |
The Motley Fool
November 5, 2007
Brian Orelli |
Last Look at Mini-Mylan An impending merger with Merck's KGaA's generic drug business should more than double revenue at Mylan. |
Pharmaceutical Executive
September 1, 2010
William Looney |
The Coming Second Act Reinvention takes more than a pithy redraft of the strategy plan or mission statement; money, a change in business culture, and the mindset of thousands of employees is required too. |
The Motley Fool
January 27, 2011
Brian Orelli |
Gilead's Once in a Decade Quarter Gilead's revenue falls for the first time in more than a decade. |
The Motley Fool
May 3, 2007 |
Teva Pharmaceutical Has Strong Quarter: Fool by Numbers The pharmaceutical released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
Chemistry World
May 4, 2011
Andrew Turley |
Teva sidelines Valeant with $6.8bn Cephalon bid US drugmaker Cephalon has agreed to a $6.8 billion ( 4.1 billion) takeover bid from Israeli generics manufacturer Teva, which has beaten into second place Canadian pharma company Valeant. |
The Motley Fool
November 25, 2010
Seth Jayson |
Don't Get Too Worked Up Over Gilead's Earnings With questionable cash flows amounting to only 5.5% of operating cash flow, Gilead's cash flows look clean. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
The Motley Fool
August 31, 2006 |
Foolish Fundamentals: Margins Margins are important, but how you use margin information is more important to your investing success. Don't stay on the surface when analyzing margins. Your portfolio will thank you for it later. |
The Motley Fool
February 1, 2007 |
Gallant Gilead Sciences: Fool by Numbers The biopharmaceutical released fourth-quarter earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
January 18, 2011
Jim Royal |
How Do These Biotechs Really Make Their Money? Break it down using the Dupont formula. |
BusinessWeek
April 25, 2005
Sarah Lacy |
BW50: Gilead's Big Growth Spurt The small biotech rivals the majors in HIV drugs. Now it must expand beyond its niche |
The Motley Fool
June 30, 2010
Brian Orelli |
Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth? |
Pharmaceutical Executive
October 1, 2005
Brad Miles |
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. |
The Motley Fool
August 17, 2010
Travers & Jayson |
Interested in Cephalon ? Start Here! Every biotech company wants to discover the cure for cancer, Alzheimer's, or Wii knee. Every biotech investor hopes to catch the next Valeant Pharmaceuticals. |
CIO
June 1, 2002
Raghavan Rajaji |
Lessons in Shareholder Value To deliver real value to the business, CIOs must make all investment decisions with the company's long-term goals in mind |
The Motley Fool
March 29, 2010
Brian Orelli |
5 Drugmakers Producing Cash for You Take greenbacks over earnings any day. |
The Motley Fool
July 27, 2010
Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
The Motley Fool
March 27, 2009
Brian Orelli |
Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with. |
CRM
May 10, 2013
Syed Hasan |
Choose a Winning Combination of Customer Experience Metrics Improve customer loyalty with the right mix of customer experience management (CEM) solutions. |
